| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
57,680,000 |
| Market
Cap: |
1.69(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.05 - $32.15 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
93,396 |
175,244 |
175,244 |
175,244 |
| Total Sell Value |
$2,858,339 |
$4,519,351 |
$4,519,351 |
$4,519,351 |
| Total People Sold |
3 |
5 |
5 |
5 |
| Total Sell Transactions |
6 |
9 |
9 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gupta Suneel |
Chief Development Officer |
• – – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
152,187 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2023-05-31 |
4 |
D |
$26.07 |
$317,142 |
D/D |
(12,165) |
602,946 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
615,111 |
|
- |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2023-05-31 |
4 |
D |
$26.07 |
$108,191 |
D/D |
(4,150) |
31,036 |
|
- |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
35,186 |
|
- |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2023-04-18 |
4 |
D |
$23.21 |
$27,597 |
D/D |
(1,189) |
23,186 |
|
- |
|
| Selick Harold E |
Director |
– • – |
2023-04-10 |
4 |
OE |
$0.87 |
$5,391 |
D/D |
6,196 |
21,506 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2023-02-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
583,448 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
3,125 |
24,375 |
|
- |
|
| Gupta Suneel |
Chief Development Officer |
• – – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,625 |
138,187 |
|
- |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,625 |
24,375 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2022-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,116 |
598,096 |
|
- |
|
| Liu David Y |
Chief R&D Strategy Officer |
• – – |
2022-11-16 |
4 |
OE |
$0.87 |
$231,802 |
D/D |
100,479 |
167,590 |
|
- |
|
| Molina Arturo Md |
Chief Medical Officer |
• – – |
2022-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,250 |
21,250 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2022-08-23 |
4 |
OE |
$4.21 |
$84,200 |
D/D |
20,000 |
604,048 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2022-05-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
581,048 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2022-05-04 |
4 |
OE |
$4.21 |
$66,274 |
D/D |
15,742 |
584,048 |
|
- |
|
| Waddill William D. |
Director |
– • – |
2022-05-03 |
4 |
OE |
$8.59 |
$103,080 |
D/D |
12,000 |
12,000 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2022-04-26 |
4 |
OE |
$4.21 |
$126,300 |
D/D |
30,000 |
568,306 |
|
- |
|
| Gupta Suneel |
Chief Development Officer |
• – – |
2022-04-26 |
4 |
OE |
$7.38 |
$295,200 |
D/D |
40,000 |
117,561 |
|
- |
|
| Ali Asif |
Chief Financial Officer |
• – – |
2022-04-18 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
13,750 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • • |
2022-04-14 |
4 |
OE |
$1.89 |
$64,424 |
D/D |
34,087 |
537,847 |
|
- |
|
| Gupta Suneel |
Chief Development Officer |
• – – |
2022-02-28 |
4 |
D |
$24.28 |
$15,758 |
D/D |
(649) |
77,007 |
|
- |
|
| Liu David Y |
Chief Scientific Officer |
• – – |
2022-02-28 |
4 |
D |
$24.28 |
$51,449 |
D/D |
(2,119) |
66,538 |
|
- |
|
| Patel Dinesh V Ph D |
President and CEO |
• • – |
2022-02-28 |
4 |
D |
$24.28 |
$112,853 |
D/D |
(4,648) |
503,760 |
|
- |
|
166 Records found
|
|
Page 2 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.09 (3.86%) 
